ISSN: 2044-9038 (Print) 2044-9046 (Electronic)

Clinical Practice

Erythropoietin

 Erythropoietin (EPO) may be a protein produced within the kidneys that stimulates the assembly of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors within the bone marrow Label. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 because the first rhEPO commercialized within the us , followed by other alfa and beta formulations. Epoetin alfa may be a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant deoxyribonucleic acid technology and is employed for the treatment of patients with anemia related to various clinical conditions, like chronic kidney failure , antiviral therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures Label. it's a relative molecular mass of roughly 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. the merchandise contains the identical aminoalkanoic acid sequence of isolated natural erythropoietin and has an equivalent biological activity because the endogenous erythropoietin. Epoetin alfa biosimilar, like Retacrit (epoetin alfa-epbx or epoetin zeta), has been formulated to permit more access to treatment options for patients within the market . The biosimilar is approved by the FDA and EMA as a secure , effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product . Epoetin alfa formulations are often administered intravenously or subcutaneously.  

High Impact List of Articles

Relevant Topics in Clinical